RCC2 and colorectal carcinoma: Loss of CDX2 expression has been proposed as a biomarker for benefit from chemotherapy in CRC, also in our patient cohorts.11 12 RCC2 seemed to be independent of CDX2 in this setting, but due to the low number of CDX2 negative cases, we cannot firmly conclude on the prognostic relationship between RCC2, CDX2 and adjuvant chemotherapy.